S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NYSE:CLB

Core Laboratories (CLB) Stock Forecast, Price & News

$23.46
-0.55 (-2.29%)
(As of 09/26/2023 ET)
Compare
Today's Range
$23.30
$24.31
50-Day Range
$23.46
$27.42
52-Week Range
$13.48
$27.94
Volume
206,054 shs
Average Volume
423,168 shs
Market Capitalization
$1.10 billion
P/E Ratio
28.27
Dividend Yield
0.17%
Price Target
$21.88

Core Laboratories MarketRank™ Forecast

Analyst Rating
Sell
1.33 Rating Score
Upside/​Downside
6.8% Downside
$21.88 Price Target
Short Interest
Bearish
12.05% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
44.07%
From $0.59 to $0.85 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Oils/Energy Sector

184th out of 238 stocks

Oil & Gas Field Services, Not Elsewhere Classified Industry

15th out of 18 stocks


CLB stock logo

About Core Laboratories (NYSE:CLB) Stock

Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, hydrogen storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. The company was founded in 1936 and is based in Houston, Texas.

CLB Price History

CLB Stock News Headlines

Citigroup Trims Core Laboratories (NYSE:CLB) Target Price to $20.00
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Equinor (EQNR) Acquires Poland Wind Farm From Helios Group
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Core Laboratories (NYSE: CLB)
Core Laboratories (CLB) Receives a Hold from Piper Sandler
Core Laboratories (CLB) Tops Q2 Earnings Estimates
Earnings Preview: Core Laboratories
4 Analysts Have This to Say About Core Laboratories
Core Laboratories Inc
See More Headlines
Receive CLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Core Laboratories and its competitors with MarketBeat's FREE daily newsletter.

CLB Company Calendar

Last Earnings
7/26/2023
Ex-Dividend for 8/28 Dividend
8/04/2023
Dividend Payable
8/28/2023
Today
9/27/2023
Next Earnings (Estimated)
10/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Oil & gas field services, not elsewhere classified
Sub-Industry
N/A
Fax
N/A
Employees
3,600
Year Founded
1936

Price Target and Rating

Average Stock Price Forecast
$21.88
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
-6.8%
Consensus Rating
Sell
Rating Score (0-4)
1.33
Research Coverage
3 Analysts

Profitability

Net Income
$19.45 million
Pretax Margin
8.39%

Debt

Sales & Book Value

Annual Sales
$489.73 million
Cash Flow
$0.92 per share
Book Value
$4.07 per share

Miscellaneous

Free Float
46,400,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
2.68

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Lawrence V. Bruno (Age 63)
    Chairman, CEO, Pres & COO
    Comp: $1.53M
  • Mr. Christopher Scott Hill (Age 53)
    Sr. VP & CFO
    Comp: $682.02k
  • Ms. Gwendolyn Y. Gresham M.B.A. (Age 55)
    Sr. VP of Corp. Devel. & Investor Relations
    Comp: $564.28k
  • Mr. Mark Damian Tattoli (Age 51)
    Sr. VP, Sec. & Gen. Counsel
    Comp: $562.44k
  • Mr. Kevin G. Daniels (Age 59)
    Chief Accounting Officer, Treasurer & VP
  • Mr. Jacobus Schouten (Age 68)
    Managing Director
  • J. Donald Dumas Jr.
    Sr. VP of Production Enhancement & Bus. Devel.













CLB Stock - Frequently Asked Questions

Should I buy or sell Core Laboratories stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Core Laboratories in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" CLB shares.
View CLB analyst ratings
or view top-rated stocks.

What is Core Laboratories' stock price forecast for 2023?

3 equities research analysts have issued 12-month price objectives for Core Laboratories' stock. Their CLB share price forecasts range from $20.00 to $25.00. On average, they anticipate the company's stock price to reach $21.88 in the next year. This suggests that the stock has a possible downside of 6.8%.
View analysts price targets for CLB
or view top-rated stocks among Wall Street analysts.

How have CLB shares performed in 2023?

Core Laboratories' stock was trading at $20.27 on January 1st, 2023. Since then, CLB shares have increased by 15.7% and is now trading at $23.46.
View the best growth stocks for 2023 here
.

Are investors shorting Core Laboratories?

Core Laboratories saw a drop in short interest in August. As of August 31st, there was short interest totaling 5,580,000 shares, a drop of 19.1% from the August 15th total of 6,900,000 shares. Based on an average trading volume of 512,400 shares, the short-interest ratio is currently 10.9 days. Approximately 12.1% of the company's stock are short sold.
View Core Laboratories' Short Interest
.

When is Core Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our CLB earnings forecast
.

How were Core Laboratories' earnings last quarter?

Core Laboratories Inc. (NYSE:CLB) issued its quarterly earnings results on Wednesday, July, 26th. The oil and gas company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.15 by $0.08. The oil and gas company earned $127.88 million during the quarter, compared to analyst estimates of $132.20 million. Core Laboratories had a net margin of 7.75% and a trailing twelve-month return on equity of 16.83%.

How often does Core Laboratories pay dividends? What is the dividend yield for Core Laboratories?

Core Laboratories announced a quarterly dividend on Wednesday, July 26th. Investors of record on Monday, August 7th will be given a dividend of $0.01 per share on Monday, August 28th. This represents a $0.04 annualized dividend and a dividend yield of 0.17%. The ex-dividend date is Friday, August 4th.
Read our dividend analysis for CLB
.

Is Core Laboratories a good dividend stock?

Core Laboratories (NYSE:CLB) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.17%. The dividend payout ratio is 4.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CLB will have a dividend payout ratio of 4.71% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CLB.

What guidance has Core Laboratories issued on next quarter's earnings?

Core Laboratories updated its third quarter 2023 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $0.21-$0.25 for the period, compared to the consensus earnings per share estimate of $0.23. The company issued revenue guidance of $128.00 million-$132.00 million, compared to the consensus revenue estimate of $135.99 million.

What is David M. Demshur's approval rating as Core Laboratories' CEO?

60 employees have rated Core Laboratories Chief Executive Officer David M. Demshur on Glassdoor.com. David M. Demshur has an approval rating of 36% among the company's employees. This puts David M. Demshur in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Core Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Core Laboratories investors own include CA (CA), BlackRock (BLK), Starbucks (SBUX), Micron Technology (MU), Chipotle Mexican Grill (CMG), Endologix (ELGX), Intel (INTC), Netflix (NFLX), AT&T (T) and Gilead Sciences (GILD).

What is Core Laboratories' stock symbol?

Core Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."

Who are Core Laboratories' major shareholders?

Core Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ariel Investments LLC (20.63%), BlackRock Inc. (16.98%), Earnest Partners LLC (8.22%), Boston Trust Walden Corp (4.71%), State Street Corp (3.96%) and Congress Asset Management Co. MA (2.08%).
View institutional ownership trends
.

How do I buy shares of Core Laboratories?

Shares of CLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Core Laboratories' stock price today?

One share of CLB stock can currently be purchased for approximately $23.46.

How much money does Core Laboratories make?

Core Laboratories (NYSE:CLB) has a market capitalization of $1.10 billion and generates $489.73 million in revenue each year. The oil and gas company earns $19.45 million in net income (profit) each year or $0.83 on an earnings per share basis.

How many employees does Core Laboratories have?

The company employs 3,600 workers across the globe.

How can I contact Core Laboratories?

Core Laboratories' mailing address is STRAWINSKYLAAN 913 TOWER A LEVEL 9, AMSTERDAM P7, 1077 XX. The official website for the company is www.corelab.com. The oil and gas company can be reached via phone at (713) 328-2673 or via email at investor.relations@corelab.com.

This page (NYSE:CLB) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -